The Panorama Prenatal Test
The unique methodology of the Panorama prenatal test utilizes single nucleotide polymorphism (SNP) technology and is much more efficient and accurate than the counting or quantitative methods used by all other available non-invasive prenatal tests.
This NATUS (Next-generation Aneuploidy Testing Using SNPs) methodology evaluates specific genetic loci on the actual mix of maternal and fetal DNA from the mother’s blood. This allows the Panorama prenatal test to provide consistent sensitivity and specificity across all chromosomes, even at low fetal fractions. The result is a patient-specific individualized risk score, and better sensitivity and specificity with a decreased chance of false positives or false negatives with a low no call rate.
While fetal fraction of DNA in the mother’s blood can vary greatly throughout gestational age, it does tend to be lower earlier in the pregnancy. By using SNP technology, the Panorama prenatal test has strong detection rates even at lower fetal fractions and can be used as early as 9 weeks gestational age.
How does Natera non-invasively examine fetal DNA?
The Panorama prenatal test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
Why The Panorama Test?
The Panorama prenatal test provides superior coverage and the best detection and accuracy over any other current screening methods.learn more
Proven by our Science
Clinical data proves the Panorama prenatal test identifies more chromosomal abnormalities than any other prenatal test, with higher accuracy than any other prenatal tests available.view data results